Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study.

导出原文传递

翻译打印收藏纠错

第一作者： Samuel,Lederman

第一单位： Altus Research, Lake Worth, FL, USA.

作者： Samuel,Lederman ^[1] ; Faith D,Ottery ^[2] ; Antonio,Cano ^[3] ; Nanette,Santoro ^[4] ; Marla,Shapiro ^[5] ; Petra,Stute ^[6] ; Rebecca C,Thurston ^[7] ; Marci,English ^[2] ; Catherine,Franklin ^[2] ; Misun,Lee ^[2] ; Genevieve,Neal-Perry ^[8]

作者单位： Altus Research, Lake Worth, FL, USA. ^[1] Astellas Pharma Global Development, Northbrook, IL, USA. ^[2] Department of Paediatrics, Obstetrics and Gynaecology, University of Valencia, Valencia, Spain. ^[3] Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, CO, USA. ^[4] Department of Family and Community Medicine, University of Toronto, Toronto, ON, Canada. ^[5] University Clinic for Gynecology, Inselspital, Bern, Switzerland. ^[6] Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA. ^[7] Department of Obstetrics and Gynecology, University of North Carolina School of Medicine, Chapel Hill, NC, USA. Electronic address: genevieve_nealperry@med.unc.edu. ^[8]